Table 2 Univariate analysis of clinical outcomes

BRAF status

 Negative

–

–

–

–

 Positive

2.7 (1.1–6.5)

0.96 (0.58–1.6)

1.20 (0.75–1.9)

1.11 (0.63–2.0)

Gender

 Male

–

–

–

–

 Female

0.46 (0.17–1.2)

0.93 (0.55–1.6)

1.04 (0.63–1.7)

0.95 (0.52–1.7)

Age

 ≤ 50 yrs

–

–

–

–

 < 50 yrs

0.77 (0.33–1.8)

1.12 (0.69–2.0)

1.14 (0.69–1.9)

1.46 (0.79–2.7)

Location of primary

 Other

–

–

–

–

 Trunk

1.01 (0.35–2.9)

0.80 (0.38–1.7)

0.86 (0.43–1.8)

0.57 (0.23–1.4)

Depth of invasion

 ≤ 2 mm

–

–

–

–

 < 2 mm

1.04 (0.43–2.5)

1.11 (0.64–1.9)

0.97 (0.58–1.6)

0.82 (0.45–1.5)

Ulceration of primary

 No

–

–

–

–

 Yes

1.04 (0.36–2.9)

1.15 (0.61–2.1)

0.96 (0.53–1.7)

1.20 (0.60–2.4)

# of Mitosis in primary

 ≤ 5

–

–

–

–

 > 5

1.20 (0.41–3.4)

1.1 (0.56–2.0)

1.01 (0.58–1.9)

1.13 (0.57–2.3)

# of LNs positive

 < 4

–

–

–

–

 ≥ 4

3.34 (1.4–8.2)

1.72 (0.92–3.2)

1.88 (1.1–3.4)

2.26 (1.19–4.3)

ECE

 No

–

–

–

–

 Yes

0.91 (0.35–2.4)

1.18 (0.62–2.2)

0.95 (0.52–1.7)

1.09 (0.56–2.1)

Size of LN deposit

 ≤ 30 mm

–

–

–

–

 > 30 mm

0.41 (0.14–1.2)

1.35 (0.75–2.4)

1.23 (0.70–2.1)

0.97 (0.51–1.9)

RT dose

 ≤ 30 Gy

–

–

–

–

 > 30 Gy

0.99 (0.46–2.2)

0.99 (0.60–1.6)

1.1 (0.68–1.8)

0.85 (0.48–1.5)

Time from LND to RT

 ≤ 3 mos

–

–

–

–

 > 3 mos

0.54 (0.7–4.0)

1.08 (0.39–3.0)

0.85 (0.30–2.4)

1.14 (0.41–3.2)

Adjuvant systemic Tx

 No

–

–

–

–

 Yes

0.74 (0.34–1.6)

0.63 (0.38–1.0)

0.61 (0.4–0.99)

0.72 (0.41–1.3)